These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1106 related items for PubMed ID: 19706799

  • 1. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.
    Clin Cancer Res; 2009 Sep 01; 15(17):5445-56. PubMed ID: 19706799
    [Abstract] [Full Text] [Related]

  • 2. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.
    Lung Cancer; 2008 May 01; 60(2):166-74. PubMed ID: 18006183
    [Abstract] [Full Text] [Related]

  • 3. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
    Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C.
    J Cell Physiol; 2012 Jul 01; 227(7):2947-52. PubMed ID: 21959795
    [Abstract] [Full Text] [Related]

  • 4. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O.
    Int J Cancer; 2006 Dec 01; 119(11):2557-66. PubMed ID: 16988945
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M.
    Cancer Res; 2005 May 15; 65(10):4253-60. PubMed ID: 15899817
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L, Wang Y, Wang H, Gao H, Liang J, Sui A, Xiang J, Zhou F, Xu C, Zhao W, Liang W, Yao R.
    Oncol Rep; 2012 Oct 15; 28(4):1453-60. PubMed ID: 22895605
    [Abstract] [Full Text] [Related]

  • 9. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
    Tandon R, Kapoor S, Vali S, Senthil V, Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK, Dastidar SG.
    Eur J Pharmacol; 2011 Sep 30; 667(1-3):56-65. PubMed ID: 21640718
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI.
    Endocr Relat Cancer; 2004 Dec 30; 11(4):793-814. PubMed ID: 15613453
    [Abstract] [Full Text] [Related]

  • 11. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
    Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK.
    Cancer Res; 2008 Apr 01; 68(7):2391-9. PubMed ID: 18381447
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C.
    J Hepatol; 2012 Jul 01; 57(1):108-15. PubMed ID: 22414764
    [Abstract] [Full Text] [Related]

  • 13. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherübl H.
    J Hepatol; 2004 Dec 01; 41(6):1008-16. PubMed ID: 15582135
    [Abstract] [Full Text] [Related]

  • 14. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 15. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R.
    Pediatr Blood Cancer; 2010 Jul 15; 55(1):67-75. PubMed ID: 20486173
    [Abstract] [Full Text] [Related]

  • 16. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR.
    Breast Cancer Res Treat; 2008 Sep 15; 111(1):79-91. PubMed ID: 17902048
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
    E C, Li J, Shao D, Zhang D, Pan Y, Chen L, Zhang X.
    Oncol Res; 2013 Sep 15; 21(2):103-10. PubMed ID: 24406046
    [Abstract] [Full Text] [Related]

  • 19. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.